Avenzo Therapeutics Acquired | Healthcare M&A Deal

RallyBio has agreed to merge with Avenzo Therapeutics, a pharmaceuticals business in the United States, for $215 million. The combined company will operate as Avenzo Therapeutics and advance a pipeline of small molecule and antibody-drug conjugate programs for oncology indications. Avenzo Therapeutics acquisition supports healthcare M&A by expanding experimental cancer assets sourced from prior biotech partnerships and strengthening clinical-stage development. The merger acquisition is a strategic acquisition by a strategic buyer, includes a $215 million financing, and is expected to close by year-end with Nasdaq trading under the AVZO ticker.